Summaries of Independent Scientist (K) Awards
Institution: Brigham and Women's Hospital
Grant Title: Improving Methods for Comparative Effectiveness Research in Cardiovascular Care
Grant Number: K08 HS017731
Duration: 5 years (2008-2012)
Total Award: $804,000
Project Description: The goal of the proposed study is to improve the validity of comparativeness effectiveness research for cardiovascular disease (CVD) using large databases by creating new databases combining claims data and clinical registries and developing/validating advanced analytic techniques to combat potential biases in claims data analyses. There are two main aims:
- Develop new databases to study comparative effectiveness of therapies in patients with heart failure (HF) or coronary artery disease (CAD).
- Develop and evaluate statistical models of advanced analytic techniques to control bias in claims data analyses assessing comparative effectiveness of therapies in patients with HF and CAD.
Career Goals: Dr. Setoguchi-Iwata is an Instructor in Medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women's Hospital. She received her MD from Miyazaki Medical College in Miyazaki Japan and served a residency in general medicine at the Kameda Medical Center in Chiba, Japan. The grantee then completed an internship in internal medicine at the University of Iowa Hospitals and Clinics in Iowa City. She went on to earn her MPH, ScM. and DrPH from Harvard School of Public Health. Dr. Setoguchi-Iwata's long term career goal is to become an outstanding researcher in health services/outcomes research for CVD with strong methodological skills, especially studying comparative effectiveness/safety of therapies in patients with CVD.
Progress to Date: This grant has just started.
Highlights and Specific Accomplishments:
- First-place poster at the International Conference for Pharmacoepidemiology in Lisbon, Portugal, 2006.
- Pharmacoepidemiology Training and Research Scholarship, Harvard, 2003.
K-Generated Publications: None thus far.